Recent Research Articles
There is good news in the advancement of chemo-free approaches to managing chronic lymphocytic leukemia, and I am thrilled to share it with you. Results of the phase III ECOG trial found that the combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) came out superior to the chemotherapy and immunotherapy (chemoimmunotherapy) grouping of fludarabine, cyclophosphamide, and rituximab, known as FCR.
Glenn shares how THC and CBD are being used in a clinical setting—and where we are in terms of current science supporting medical marijuana and CBD oil for symptom relief and as an anticancer agent. He also shares his own history with cannabinoids.
Glenn explores the phenomena of cancer outliers, exceptional responders and radical remissions in the age of precision medicine, biomedical informatics and integrative oncology.
A recently published paper in the esteemed JAMA Oncology triggered dire headlines, including this one in The New York Times:
“People who used herbs, acupuncture and other complementary treatments tended to die earlier than those who didn’t.”
Really? Is this true?
For 20 years, the Environmental Working Group (EWG) has been the stalwart investigative organization scrutinizing unsafe chemicals and toxins in our food, water, cosmetics, and cleaning products.
Given the easy access to direct-to-consumer (DTC) DNA testing, it is vital to discern the potential value versus possible emotional and physical risks that having such data might present.
Investigation of the human microbiome has grown exponentially in the last five years. A recent study regarding its potential impact on certain cancer treatment outcomes stopped me in my tracks. The human body contains about 40 trillion microbes, which is now thought to equal the total volume of human cells each body possesses. These bugs […]
The Right-to-Try movement—advocates for faster access to potentially life-saving experimental drugs for terminal patients—has gained strong momentum, with the act recently winning easy passage in congress, and, at the time of this article, it is on its way for a senate vote. The legislation is widely anticipated to become law later this year. As of […]
We are hearing a lot about cancer immunotherapy these days. Modern approaches and technology are now helping to revolutionize cancer care. What decision-making power do we hold to influence an immune-therapeutic response to help avoid, manage, or treat a cancer diagnosis? And how might this affect long-term survival?
The importance of disseminating accurate information on evidence-informed integrative cancer care approaches led to the founding of the Society for Integrative Oncology (SIO) in 2003. SIO recently spearheaded the publication in JNCI Institute Monographs, titled ‘Advancing the Global Impact of Integrative Oncology’.